Mirtazapine and Folate for Idiopathic Schizophrenia, but for which Autism?

 China, where things tend to be big, even their clinical trials

A short while ago we looked at the possible mechanisms behind a reader’s successful experience in use of Mirtazapine (Remeron) in autism, then being prescribed to increase appetite.

Mirtazapine is a tricyclic antidepressant, meaning it is very closely related to first generation antihistamines, but it has numerous other effects;  more of that later.

Folate is vitamin B9.  Folic acid is synthetically produced, and used in fortified foods and supplements on the theory that it is converted into folate, which may not be the case.

It appears that in both schizophrenia and autism there is a family of possible folate dysfunctions that range from minor to severe.  The mild dysfunction responds to a small supplement of folate, while the severe dysfunction requires a much larger supplement of folate.

Roger, another reader of this blog has the more severe dysfunction called Cerebral Folate Deficiency (CFD) and this condition is best studied by Vincent Ramaekers  (Department of Pediatric Neurology and Center of Autism, University Hospital Liege) and Richard Frye at the Arkansas Children’s Hospital.

Cerebral folate deficiency as diagnosed by Ramaekers/Frye is extremely rare.

In a previous post we looked at Biotin (vitamin B7) and we saw that while biotin/biotinidase deficiency is technically extremely rare, a partial deficiency seems to exist in about 5% of people with autism.  

Both severe biotin/biotinidase deficiency and partial biotin/biotinidase deficiency responds well to high dose biotin supplementation.

Without going into the details of Folate Receptor Autoantibodies (FRAs), it is clear that Ramaekers has found the same condition in both Schizophrenia and Autism.

The milder folate dysfunction is very well known in schizophrenia.

The Chinese Trial

On the basis that bigger is better, a clinical trial is underway in China on 330 subjects with Schizophrenia to measure the benefit of Mirtazapine and/or folate as an add-on therapy.

Evaluation of Mirtazapine and Folic Acid for Schizophrenia:(RECOVERY2)

I was quite surprised to come across this trial.

Today’s Post

Today’s post will look at the known effects of Mirtazapine and folate in schizophrenia and also the role folate plays in human biology.

There are lab tests that you could make to check for Folate dysfunction, just as there are for Biotin dysfunction. 

The standard therapy for Cerebral Folate Deficiency is the prescription drug leucovorin, normally used in cancer therapy.  There is also a supplement called Metafolin (Levomefolate calcium) that should have a very similar, if not identical, effect. Metafolin is produced by Merck and sold to supplement companies on the basis that it is only sold in low doses.  Metafolin appears more than your average “supplement”.

Another producer of Levomefolate calcium, is Pamlab; they sell it as a treatment for memory loss and peripheral neuropathy.  Pamlab was purchased by Nestlé Health Science in 2013; the Swiss tend to know what they are doing.

Schizophrenia

Schizophrenia overlaps significantly with autism in terms of its genetic origin.

Interestingly, people with schizophrenia may have a high rate of irritable bowel syndrome, but they often do not mention it unless specifically asked.

To better understand the clinical trials you need to know that the schizophrenia is a spectrum like autism with three main problem areas:-

Positive symptoms

These are symptoms that most individuals do not normally experience but are present in people with schizophrenia. They can include delusions, disordered thoughts and speech, and tactile, auditory, visual, olfactory and gustatory hallucinations, typically regarded as manifestations of psychosis. Hallucinations are also typically related to the content of the delusional theme. Positive symptoms generally respond well to medication.

Negative symptoms

These are deficits of normal emotional responses or of other thought processes, and are less responsive to medication. They commonly include flat expressions or little emotion, poverty of speech, inability to experience pleasure,lack of desire to form relationships, and lack of motivation. Negative symptoms appear to contribute more to poor quality of life, functional ability, and the burden on others than do positive symptoms. People with greater negative symptoms often have a history of poor adjustment before the onset of illness, and response to medication is often limited.

 

Cognitive dysfunction

The extent of the cognitive deficits an individual experiences is a predictor of how functional an individual will be, the quality of occupational performance, and how successful the individual will be in maintaining treatment.  The presence and degree of cognitive dysfunction in individuals with schizophrenia has been reported to be a better indicator of functionality than the presentation of positive or negative symptoms

Effective psychiatric drugs only exist for the positive symptoms, they do not exist for the negative symptoms or the cognitive dysfunction.

Folate Deficiency in Schizophrenia

Folate treatment in schizophrenia is linked to improvement in the negative symptoms that are normally untreatable.

Studies are mixed, but subgroups clearly exist in schizophrenia where folate supplementation improved well-being.

The rare severe dysfunction which is Cerebral Folate Deficiency is shown to exist in schizophrenia. 

Folate and vitamin B12 supplementation reduces disabling schizophrenia symptoms in patients with specific gene variants

Participants were all taking antipsychotic medications – which have been shown to alleviate positive symptoms, such as hallucinations and delusions, but not negative symptoms – and were randomized to receive daily doses of either folate and vitamin B12 or a placebo for 16 weeks. Every two weeks their medical and psychiatric status was evaluated, using standard symptom assessment tools along with measurements of blood levels of folate and homocysteine, an amino acid that tends to rise when folate levels drop. Nutritional information was compiled to account for differences in dietary intake of the nutrients. Participants' blood samples were analyzed to determine the variants they carried of MTHFR and three other folate-pathway genes previously associated with the severity of negative symptoms of schizophrenia. 

Among all 140 participants in the study protocol, those receiving folate and vitamin B12 showed improvement in negative symptoms, but the degree of improvement was not statistically significant compared with the placebo group. But when the analysis accounted for the variants in the genes of interest, intake of the two nutrients did provide significant improvement in negative symptoms, chiefly reflecting the effects of specific variants in MTHFR and in a gene called FOLH1. Variants in the other two genes studied did not appear to have an effect on treatment outcome.

  

Folate and vitamin B12 status in schizophrenic patients

CONCLUSIONS:

This study showed that folate deficiency is common in schizophrenic patients; therefore, it is important to pay attention to folate levels in these patients.

Folinic acid treatment for schizophrenia associated with folate receptor autoantibodies

  

The Role of Folate/vitamin B9 in Human Biology

Vitamin B₉ is essential for numerous bodily functions. Humans cannot synthesize folates de novo; therefore, folic acid has to be supplied through the diet to meet their daily requirements. The human body needs folate to synthesize DNA, repair DNA, and methylate DNA as well as to act as a cofactor in certain biological reactions.

Folic acid is synthetically produced, and used in fortified foods and supplements on the theory that it is converted into folate.  To be used it must be converted to tetrahydrofolate (tetrahydrofolic acid) by dihydrofolate reductase (DHFR). Increasing evidence suggests that this process may be slow in humans.

Note betaine below, which is also used to treat Cerebral Folate Deficiency, along with NAC.

Source: https://commons.wikimedia.org/wiki/File:MTHFR_metabolism.svg

Folic Acid, Folinic Acid and Folate

The terminology is confusing; what we want is folate, but there are several ways to get it.  Folic acid does not appear to be a good way.  Folinic acid, Levomefolic acid and Levomefolate calcium look to be the most effective supplements.

Here is a brief summary from Wikipedia:_

Folinic acid  or leucovorin, generally administered as the calcium or sodium salt (calcium folinate, sodium folinate, leucovorin calcium, leucovorin sodium), is an adjuvant used in cancer chemotherapy involving the drug methotrexate. It is also used in synergistic combination with the chemotherapy agent 5-fluorouracil.

Folinic acid (also called 5-formyltetrahydrofolate) was first discovered in 1948 as citrovorum factor and occasionally is still called by that name. Folinic acid should be distinguished from folic acid (vitamin B₉). However, folinic acid is a vitamer for folic acid, and has the full vitamin activity of this vitamin.

Levomefolic acid is the primary biologically active form of folic acid used at the cellular level for DNA reproduction, the cysteine cycle and the regulation of homocysteine. It is also the form found in circulation and transported across membranes into tissues and across the blood-brain barrier. In the cell, L-methylfolate is used in the methylation of homocysteine to form methionine and tetrahydrofolate (THF). THF is the immediate acceptor of one carbon units for the synthesis of thymidine-DNA, purines (RNA and DNA) and methionine. The un-methylated form, folic acid (vitamin B₉), is a synthetic form of folate, and must undergo enzymatic reduction by methylenetetrahydrofolate reductase (MTHFR) to become biologically active.

It is synthesized in the absorptive cells of the small intestine from polyglutamylated dietary folate. It is a methylated derivative of tetrahydrofolate. Levomefolic acid is generated by MTHFR from 5,10-methylenetetrahydrofolate (MTHF) and used to recycle homocysteine back to methionine by 5-methyltetrahydrofolate-homocysteine methyltransferase(MTR) also known as methionine synthase (MS).
Levomefolic acid (and folic acid in turn) has been proposed for treatment of cardiovascular disease and advanced cancers such as breast and colorectal cancers. It bypasses several metabolic steps in the body and better binds thymidylate synthase with fDump, a metabolite of the drug fluorouracil.

Levomefolate calcium, a calcium salt of levomefolic acid, is sold under the brand names Metafolin (a registered trademark of Merck KGaA) and Deplin (trademark of Pamlab, LLC). Methyl folate can be bought at online stores or in some chemists though without a prescription.

A good choice seems to be Metafolin, like in this product:-

Folate and Autism

We know from Roger and Frye/Ramaekers that the rare condition condition Cerebral folate deficiency (CFD) exists in autism, but what about the more widespread milder dysfunction like that found in schizophrenia?

As usual the level of knowledge in autism is less than that in schizophrenia.  The paper below concludes that when it comes to autism, not much is known.

Folic acid and autism: What do we know?

 

Autism spectrum disorders (ASD) consist in a range of neurodevelopmental conditions that share common features with autism, such as impairments in communication and social interaction, repetitive behaviors, stereotypies, and a limited repertoire of interests and activities. Some studies have reported that folic acid supplementation could be associated with a higher incidence of autism, and therefore, we aimed to conduct a systematic review of studies involving relationships between this molecule and ASD. The MEDLINE database was searched for studies written in English which evaluated the relationship between autism and folate. The initial search yielded 60 potentially relevant articles, of which 11 met the inclusion criteria. The agreement between reviewers was κ = 0.808. The articles included in the present study addressed topics related to the prescription of vitamins, the association between folic acid intake/supplementation during pregnancy and the incidence of autism, food intake, and/or nutrient supplementation in children/adolescents with autism, the evaluation of serum nutrient levels, and nutritional interventions targeting ASD. Regarding our main issue, namely the effect of folic acid supplementation, especially in pregnancy, the few and contradictory studies present inconsistent conclusions. Epidemiological associations are not reproduced in most of the other types of studies. Although some studies have reported lower folate levels in patients with ASD, the effects of folate-enhancing interventions on the clinical symptoms have yet to be confirmed.

Given the anecdotal evidence, including from our reader Seth, and the close biological relationship between autism and schizophrenia it seems pretty clear that a sub-group of people with autism do have a folate dysfunction that should respond to supplementation.  

How big this subgroup is remains to be seen.  For biotin it is about 5%, for vitamin B12 it about 10%.  Given it is known that MTHFR mutations are very common in autism, for example 23% were found to have the homozygous mutation 677CT allele (see the study below), it is very likely to be a sizeable group.  MTHFR is only one of the genes that could cause a folate problem.

Association of MTHFR Gene Variants with Autism

A trial of metafolin could be a rewarding experience for some.

Back to the second half of that big Chinese Trial - Mirtazapine

There is a wealth of research that looks into the benefit of Mirtazapine in schizophrenia.  I choose to highlight a study from Finland because it is extremely comprehensive.

Effects of add-on mirtazapine on neurocognition in schizophrenia

It has been reported earlier, from another part of this study, that clear-cut differences in all PANSS subscales and a large effect size of 1,00 (CI95% 0,23-1,67) on the PANSS total scores resulted from mirtazapine treatment when compared with a placebo in both within group and between group analyses during the double-blind phase (Joffe et al. 2009). In the open label phase, patients who switched to mirtazapine treatment demonstrated a clinical improvement in the same manner as their mirtazapine-treated counterparts in the double-blind phase. Prolonged treatment with mirtazapine led to more prominent improvements in clinical parameters than short-term treatment. A trend towards improvement was seen in all measured parameters, therefore providing more evidence of mirtazapine’s beneficial effect on schizophrenia symptoms.

The actual mechanism for a potential neurocognitive enhancing effect of mirtazapine in schizophrenia remains unknown, but it may be elucidated from its receptor binding profile. Like most SGAs, mirtazapine could also increase prefrontal dopaminergic and noradrenergic activity via 5-HT2A or 5-HT2C receptor blockade, as demonstrated in animal models (Liegeois et al. 2002; Meneses 2007; Zhang et al. 2000), and thus improve neurocognitive performance. Secondly, 5-HT3 receptor modulation by mirtazapine could also improve neurocognition (Akhondzadeh et al. 2009), presumably through increased release of acetylcholine (Ramirez et al. 1996). Thirdly, mirtazapine might improve neurocognition as a result of the indirect agonism of 5-HT1A receptors (Sumiyoshi et al. 2007). Moreover, mirtazapine is a more potent alpha-2 receptor antagonist than clozapine, which may explain its additional neurocognition-enhancing effect, even if it is added to clozapine (as in the study reported by Delle Chiae et al. 2007). The alpha-2 receptors remain an important target for neurocognitive research and its down-regulation may enhance neurocognition through a noradrenaline-mediated modulation of response to environmental stimuli (Friedman et al. 2004). Furthermore, alpha-2 receptor antagonism seems to boost hippocampal neurogenesis (Rizk et al. 2006). Also, mirtazapine may actually boost levels of brain-derived neurotrophic factor (BDNF) Rogoz et al. 2005), which is a major mediator of neurogenesis 62 and neuroplasticity. Correspondingly, those who suffer from schizophrenia often have abnormally low BDNF serum levels (Rizos et al. 2008).

During the 6-week extension phase, patients who had previously received six weeks of mirtazapine and those on placebo both showed significant improvement on several neurocognitive tests. Twelve-week mirtazapine treatment demonstrated better neurocognitive outcome than just six weeks of mirtazapine treatment, as evaluated by Stroop Dots time and TMT-B, number of mistakes, which are associated with general improvement in mental speed/attention control and executive functions. Twelve-week mirtazapine add-on to antipsychotic treatment indicated additional neurocognitive improvements of just six weeks, which demonstrates a progressive therapeutic effect.

In earlier posts on Mirtazapine/Remeron I raised various possible modes of action and other readers added their further ideas.

The table below lists some of the possible modes of action.  I declare a bias towards the importance of histamine, but clearly many more things are involved.

A Review of the Pharmacological and Clinical Profile of Mirtazapine

Mirtazapine has been trialed for a vast range of conditions:

A Review of Therapeutic Uses of Mirtazapine in Psychiatric and Medical Conditions

Mirtazapine is an effective antidepressant with unique mechanisms of action. It is characterized by a relatively rapid onset of action, high response and remission rates, a favorable side-effect profile, and several unique therapeutic benefits over other antidepressants. Mirtazapine has also shown promise in treating some medical disorders, including neurologic conditions, and ameliorating some of the associated debilitating symptoms of weight loss, insomnia, and postoperative nausea and vomiting.

And even Fibromyalgia, which I did suggest was the “almost autism” for females:-

In a 6-week open-label trial of mirtazapine, 54% of the 26 fibromyalgia patients who completed the study demonstrated a clinically significant reduction in pain intensity and in mean weekly dosage of acetaminophen. Additionally, there was a significant improvement in sleep quality and somatic symptoms, including cold extremities, dry mouth, sweating, dizziness, and headache. Of note, the magnitude of reduction in major fibromyalgia symptoms was significantly correlated with the magnitude of reduction in depression

Mirtazapine in Autism

In the new trial of Mirtazapine in autism they have chosen to focus on anxiety.  That looks odd to me given the very wide scope of benefits seen in schizophrenia and the feedback of our reader who asked why Remeron was working wonders with his child.

As is often the case, this trial at Massachusetts General Hospital uses doses that are extremely high.  Given the numerous effects of this drug it is highly likely that the effect may be completely different at higher/lower doses.

Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

This study will determine the effectiveness of mirtazapine in reducing anxiety in children with autistic disorder, Asperger's disorder and Pervasive Developmental Disorder.

The starting dose for subjects is 7.5 mg daily. The maximum daily dose will be 45 mg.

I am very much in agreement with the readers of this blog using Mirtazapine at a lower dose.

As the schizophrenia trial showed, the effect grows over time, so better to try a low dose of 5mg for two months than race up to 45mg. 

Intranasal Insulin for Improved Mood and Cognition

  

This post follows on the previous one that raised the issue of brain-specific insulin sensitivity being a common feature of neurological diseases/disorders.

It appears to be much more than just a rare possibility.   There have been numerous studies and even more are ongoing.

Intranasal insulin has even been tried one single-gene type of autism (Phelan-McDermid Syndrome) and in autism’s big brothers, bipolar and schizophrenia.

I did look for trials in children with Down Syndrome, since here is a direct link to Alzheimer’s, but there is just a trial in adults in progress.

There was an early trial in typical adults which is interesting since it found not only a cognitive improvement but also improved mood, so perhaps it should be trialed in adults with depression.  In the US, interestingly, T3 thyroid hormone is sometimes given off-label for depression and some antidepressants increase the conversion of the pro-hormone T4 to T3 in the brain.  I think central hypothyroidism is likely a feature of some neurological disorders, as I proposed in an earlier post.

I think it would be well worth trialing intranasal insulin in idiopathic Autism and, separately, idiopathic Asperger’s.  I am surprised nobody has done it. I really think Autism and Asperger’s  should be separated, since while we sometimes see the same therapy helps in both, sometimes there are Asperger-specific therapies, like Baclofen.

A small number of readers of this blog do follow the science and engage in some experimentation at home.  I think given what some people have already tried, intranasal insulin is not at all far fetched, you just need a metered dose nasal spray, insulin and the correct amount of dilutant/diluent, as in the trials.

Insulin and IGF-1 (insulin-like growth factor 1)

There are autism trials underway using subcutaneous injections of IGF-1 and also oral IGF-1 analogs.

IGF-1 is a primary mediator of the effects of growth hormone (GH). Growth hormone is made in the anterior pituitary gland, is released into the blood stream, and then stimulates the liver to produce IGF-1. IGF-1 then stimulates systemic body growth, and has growth-promoting effects on almost every cell in the body,

Insulin levels affect levels of growth hormone (GH) and IGF-1.

We know that various growth factors (NGF, BDNF, IGF-1 etc.) in people with autism can be disturbed, but there is both hypo and hyper.

We also know that the level of hormones measured in the blood can be very different to those in the brain/CNS.  This means that having blood tests indicating  high serotonin, thyroid T3, IGF-1 etc. does not tell you anything about the level within the brain.  Quite possibly they may be the opposite.

It would seem to be hugely preferable to target the brain directly, rather than the whole body.

The lack of side effects in the numerous studies of intranasal insulin is very encouraging.

Healthy Neurotypical Adults

Intranasal insulin improves memory in humans

Declarative memory in humans without causing systemic side effects like hypoglycaemia. The improvement of memory in the eighth week of treatment corroborates previous findings of improved memory function following acute intravenous administration of the peptide both in healthy subjects (Kern et al., 2001) and in patients with Alzheimer’s disease (Craft et al., 1999). In addition, intranasal insulin positively affected mood in our subjects. The improving effect of subchronic intranasal insulin administration appeared to be specific for hippocampus dependent declarative memory.

Our subjects in the insulin group also expressed enhanced mood. Acute intranasal intake of insulin enhanced the feelings of well-being and self-confidence, which is in accordance with previous results (Kern et al., 1999).

In summary our data indicate that prolonged intranasal intake of insulin improves both consolidation of words and general mood. These beneficial findings suggest intranasal administration of insulin as a potential treatment in patients showing memory deficits in conjunction with a lack of insulin, such as in Alzheimer’s disease

Adults with Schizophrenia

No effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia.

Abstract

OBJECTIVE:

This study examined the effect of adjunctive intranasal insulin therapy on psychopathology and cognition in patients with schizophrenia.

METHODS:

Each subject had a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of schizophrenia or schizoaffective disorder and been on stable antipsychotics for at least 1 month. In an 8-week randomized, double-blind, placebo-controlled study, subjects received either intranasal insulin (40 IU 4 times per day) or placebo. Psychopathology was assessed using the Positive and Negative Syndrome Scale and the Scale for Assessment of Negative Symptoms. A neuropsychological battery was used to assess cognitive performance. The assessment for psychopathology and cognition was conducted at baseline, week 4, and week 8.

RESULTS:

A total of 45 subjects were enrolled in the study (21 in the insulin group and 24 in the placebo group). The mixed model analysis showed that there were no significant differences between the 2 groups at week 8 on various psychopathology and cognitive measures (P > 0.1).

CONCLUSIONS:

Adjunctive therapy with intranasal insulin did not seem to be beneficial in improving schizophrenia symptoms or cognition in the present study. The implications for future studies were discussed.

Adults with Bipolar

A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder.

 

Abstract

BACKGROUND:

Neurocognitive deficits are prevalent, persistent, and implicated as mediators of functional impairment in adults with bipolar disorder. Notwithstanding progress in the development of pharmacological treatments for various phases of bipolar disorder, no available treatment has been proven to be reliably efficacious in treating neurocognitive deficits. Emerging evidence indicates that insulin dysregulation may be pertinent to neurocognitive function. In keeping with this view, we tested the hypothesis that intranasal insulin administration would improve measures of neurocognitive performance in euthymic adults with bipolar disorder.

METHODS:

Sixty-two adults with bipolar I/II disorder (based on the Mini International Neuropsychiatric Interview 5.0) were randomized to adjunctive intranasal insulin 40 IU q.i.d. (n = 34) or placebo (n = 28) for eight weeks. All subjects were prospectively verified to be euthymic on the basis of a total score of ≤ 3 on the seven-item Hamilton Depression Rating Scale (HAMD-7) and ≤ 7 on the 11-item Young Mania Rating Scale (YMRS) for a minimum of 28 consecutive days. Neurocognitive function and outcome was assessed with a neurocognitive battery.

RESULTS:

There were no significant between-group differences in mean age of the subjects {i.e., mean age 40 [standard deviation (SD) = 10.15] years in the insulin and 39 [SD = 10.41] in the placebo groups, respectively}. In the insulin group, n = 27 (79.4%) had bipolar I disorder, while n = 7 (21.6%) had bipolar II disorder. In the placebo group, n = 25 (89.3%) had bipolar I disorder, while n = 3 (10.7%) had bipolar II disorder. All subjects received concomitant medications; medications remained stable during study enrollment. A significant improvement versus placebo was noted with intranasal insulin therapy on executive function (i.e., Trail Making Test-Part B). Time effects were significant for most California Verbal Learning Test indices and the Process Dissociation Task-Habit Estimate, suggesting an improved performance from baseline to endpoint with no between-group differences. Intranasal insulin was well tolerated; no subject exhibited hypoglycemia or other safety concerns.

CONCLUSIONS:

Adjunctive intranasal insulin administration significantly improved a single measure of executive function in bipolar disorder. We were unable to detect between-group differences on other neurocognitive measures, with improvement noted in both groups. Subject phenotyping on the basis of pre-existing neurocognitive deficits and/or genotype [e.g., apolipoprotein E (ApoE)] may possibly identify a more responsive subgroup

Children with Phelan-McDermid Syndrome 

22q13 deletion syndrome is a genetic disorder caused by deletions or rearrangements on the q terminal end (long arm) of chromosome 22. Any abnormal genetic variation in the q13 region that presents with significant manifestations typical of a terminal deletion should be diagnosed as 22q13 deletion syndrome. 22q13 deletion syndrome is often placed in the more general category of Phelan-McDermid Syndrome (abbreviated PMS), which includes some mutations and microdeletions. 

Physical

·         Absent to severely delayed speech: 99%

·         Normal to accelerated growth: 95%

·         High tolerance to pain: 77%

·         Hypotonia (poor muscle tone): 75%

·         Dysplastic toenails: 73%

·         Long eyelashes: 73%

·         Poor thermoregulation: 68%

·         Prominent, poorly formed ears: 65%

·         Large or fleshy hands: 63%

·         Pointed chin: 62%

·         Dolichocephaly (elongated head): 57%

·         Ptosis (eyelid) (droopy eyelids): 57%

·         Gastroesophageal reflux: 42%

·         Epileptic seizures: 27%

·         Kidney problems: 26%

·         Delayed ability to walk: 18%

Behavioral

·         Chewing on non food items: 85%

·         Delayed or unreliable toileting: 76%

·         Impulsive behaviors: 47%

·         Biting (self or others): 46%

·         Problems sleeping: 46%

·         Hair pulling: 41%

·         Autistic behaviors: 31%

·         Episodes of non-stop crying before age 5: 30%

·         Teeth grinding: (unknown) %

Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial.

 

BACKGROUND:

The 22q13 deletion syndrome (Phelan-McDermid syndrome) is characterised by a global developmental delay, absent or delayed speech, generalised hypotonia, autistic behaviour and characteristic phenotypic features. Intranasal insulin has been shown to improve declarative memory in healthy adult subjects and in patients with Alzheimer disease.

AIMS:

To assess if intranasal insulin is also able to improve the developmental delay in children with 22q13 deletion syndrome.

METHODS:

We performed exploratory clinical trials in six children with 22q13 deletion syndrome who received intranasal insulin over a period of 1 year. Short-term (during the first 6 weeks) and long-term effects (after 12 months of treatment) on motor skills, cognitive functions, or autonomous functions, speech and communication, emotional state, social behaviour, behavioural disorders, independence in daily living and education were assessed.

RESULTS:

The children showed marked short-term improvements in gross and fine motor activities, cognitive functions and educational level. Positive long-term effects were found for fine and gross motor activities, nonverbal communication, cognitive functions and autonomy. Possible side effects were found in one patient who displayed changes in balance, extreme sensitivity to touch and general loss of interest. One patient complained of intermittent nose bleeding.

CONCLUSIONS:

We conclude that long-term administration of intranasal insulin may benefit motor development, cognitive functions and spontaneous activity in children with 22q13 deletion syndrome.

For intranasal administration, insulin (40 IU/ml; Actrapid, Novo Nordisk, Mainz, Germany) was diluted with 0.9% saline solution to a concentration of 20 IU/ml so that each 0.1 ml puff with the nasal atomizer (Aero Pump, Hochheim, Germany) contained a dose of 2 IU insulin. Subjects received one dose of 2 IU insulin per day during the first 3 days according to the standard subcutaneous insulin therapy in children with type 1 diabetes mellitus. In three-day intervals, administration was increased gradually, until the final dosage of about 0.5-1.5 IU/kg/d (TID)

As with idiopathic autism there is interest in using the related IGF-1 as a therapy.

A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome

Background

Autism spectrum disorder (ASD) is now understood to have multiple genetic risk genes and one example is SHANK3. SHANK3 deletions and mutations disrupt synaptic function and result in Phelan-McDermid syndrome (PMS), which causes a monogenic form of ASD with a frequency of at least 0.5% of ASD cases. Recent evidence from preclinical studies with mouse and human neuronal models of SHANK3 deficiency suggest that insulin-like growth factor-1 (IGF-1) can reverse synaptic plasticity and motor learning deficits. The objective of this study was to pilot IGF-1 treatment in children with PMS to evaluate safety, tolerability, and efficacy for core deficits of ASD, including social impairment and restricted and repetitive behaviors.

Methods

Nine children with PMS aged 5 to 15 were enrolled in a placebo-controlled, double-blind, crossover design study, with 3 months of treatment with IGF-1 and 3 months of placebo in random order, separated by a 4-week wash-out period.

Results

Compared to the placebo phase, the IGF-1 phase was associated with significant improvement in both social impairment and restrictive behaviors, as measured by the Aberrant Behavior Checklist and the Repetitive Behavior Scale, respectively. IGF-1 was found to be well tolerated and there were no serious adverse events in any participants.

Conclusions

This study establishes the feasibility of IGF-1 treatment in PMS and contributes pilot data from the first controlled treatment trial in the syndrome. Results also provide proof of concept to advance knowledge about developing targeted treatments for additional causes of ASD associated with impaired synaptic development and function.

Drug administration

IGF-1 (Increlex; Ipsen Biopharmaceuticals, Inc) is an aqueous solution for injection containing human insulin-like growth factor-1 (rhIGF-1) produced by recombinant DNA technology. Placebo consisted of saline prepared in identical bottles by the research pharmacy at Mount Sinai. We received an Investigational New Drug exemption from the Food and Drug Administration (#113031) to conduct this trial in children with PMS. Based on the package insert for Increlex, dose titration was initiated at 0.04 mg/kg twice daily by subcutaneous injection, and increased, as tolerated, every week by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily. This titration was justified based on our preclinical data, which indicated that 0.24 mg/kg/day is effective in reversing electrophysiological deficits whereas 0.12 mg/kg/day was not as effective[21]. We aimed to reach the therapeutic dose as quickly as is safe and tolerated in order to allow maximum time for clinical improvement. Doses could be decreased according to tolerability by 0.04 mg/kg per dose. Medication was administered twice daily with meals, and preprandial glucose monitoring was performed by parents prior to each injection throughout the treatment period. Parents were carefully trained in finger stick monitoring, symptoms of hypoglycemia, and medication administration.

Down Syndrome

The ongoing Down Syndrome trial is in adults.  As mentioned earlier, a feature of the syndrome is the likely early onset of Alzheimer’s, so not surprisingly if intranasal insulin helps people with Alzheimer’s it makes sense to trial it on people with Down Syndrome.

I think it makes sense to trial it on young people with Down Syndrome, prior to the onset of Alzheimer’s.

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

This study is a single center, randomized, double-blind, placebo-controlled, cross-over pilot study designed to assess the safety of intranasally (IN) delivered glulisine versus placebo in patients with DS. Subjects will be randomized into this cross-over study and within subject comparisons conducted between single treatment of intranasal insulin glulisine and single treatment of intranasal placebo

The SNIFF (Study of Nasal Insulin in the Fight against Forgetfulness) Trials

The large clinical trials all relate to Alzheimer’s.  The big trial, SNIFF INI, will last for 18 months, but they are also making shorter trials using different types of insulin.  There is  SNIFF Quick to test fast acting insulin and SNIFF long to test the long acting type.

SNIFF Quick

SNIFF Long

SNIFF INI

The big 18 month study.

Conclusion

I think in a couple of decade’s time, it will be widely recognized that various physiological states exist in many complex diseases and while it may not be possible to cure those conditions, you can treat those altered physiological states.

In the case of autism those states might include:-

·        Oxidative stress

·        Mitochondrial stress

·        Microglial activation

·        Central hormonal dysfunction

·        Reduced brain insulin sensitivity

·        Impaired remyelination

·        Faulty GABA switch

These altered states are in addition to the specific channelopathies and other dysfunctions a particular person might have.

By applying what is learnt from other diseases we can then better treat the autism variants.  So what eventually develops from MS research in regard to remyelination can be translated to some autism variants, quite possibly that of Hannah Poling (mitochondrial disease, triggered by vaccination).

Reduced brain insulin sensitivity, where present, appears very treatable today.  I suspect some variants of autism do indeed feature reduced brain insulin sensitivity, but others will not.  There is no clever way to predict this, but it looks simple to test.

Verapamil use in Autism – Request for Case Reports from Parents

  

 By Agnieszka Wroczyńska, MD, PhD, 

Medical University of Gdansk, Poland

In June 2014 my son with severe autism was given verapamil as an emergency mast cell stabilizer according to Peter’s blog, as we run out of other medication ordered from abroad. This turned out to be a life changing moment for him and my family. Two days later his chronic diarrhea resolved completely and soon after we also saw improvements in other symptoms and behaviors.

Several months, blog entries and papers read later my son still uses verapamil and now also other medications targeting autism, most of them being included into Peter’s PolyPill. He is still significantly affected by ASD, but his quality of life improved much, thanks to this blog.

Recently I have visited a very open-minded pediatrician, the first one who suspected medical issues behind challenging behaviours in my son and she asked me about papers on verapamil use in ASD, possibly to include it into her clinical practice. Unfortunately I have nothing to recommend although the use of calcium channel blockers for autism had been suggested long before my son was born as in this paper written in 2004: “These findings hint at a potential mechanism that might underlie autism. Future studies will focus on the genetic analysis of Cav1.2 and other calcium channels in the disorder and the potential application of calcium channel blocker therapy” [1]. This did not happen and no clinical trials were done.

Calcium signalling role in ASD is well backed by science [2-5] as Peter described in many excellent posts here, but not a single case report of such treatment was published. That’s why I would like to invite readers who use or used verapamil (short or long term with or without effects) to jointly publish an article on this treatment in a peer-reviewed medical journal as a case series description.  

According to what Peter suggested before, I wrote a questionnaire including basic clinical data and - if available - tests results suggested by Peter and Nat, as a first step to this article. I would really appreciate your contribution, comments or questions about this idea.

There is no deadline date so you are welcome to join if you start verapamil treatment for you or your child in the future. You may consider to do some lab tests according to the questionnaire then.

If you have not used verapamil, but would like to join this idea in other way, please feel free to contact me.

Before the collective article is ready let me quote a recent paper on another class of calcium channel blocking drugs in autism: “Given the excellent toxicity profile of dihydropyridine LTCC blockers, long-term off-label treatment of patients with ASD appears justified based on our robust in vitro findings.” [6]

If you have not used verapamil, but would like to join this idea in other way or just discuss autism treatment without participating in this case series report, please feel free to contact me.


Thank you!

  

Agnieszka Wroczyńska, MD, PhD

Medical University of Gdansk, Poland

verapamil.asd@gmail.com

The questionnaire can be downloaded from here:

https://docs.google.com/document/d/1-xDYulhApgmwTv-hmXGQQBUo976mwzda/edit

The questionnaire filled with my son’s details as an example:

https://docs.google.com/document/d/1p7ShmEN-WrP-03kixLH3pAG0ZphjEGWWOFGOvaBrPUI/edit

[1] http://www.nature.com/nrn/journal/v5/n11/full/nrn1548.html

[2]http://www.ncbi.nlm.nih.gov/pubmed/24204377

[3] http://www.ncbi.nlm.nih.gov/pubmed/23675382

[4]http://www.ncbi.nlm.nih.gov/pubmed/19154521

[5] http://autismcalciumchannelopathy.com

[6] http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401440/